Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 896

1.

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial.

Walsh JS, Marshall H, Smith IL, Greenfield DM, Swain J, Best E, Ashton J, Brown JM, Huddart R, Coleman RE, Snowden JA, Ross RJ.

PLoS Med. 2019 Nov 12;16(11):e1002960. doi: 10.1371/journal.pmed.1002960. eCollection 2019 Nov.

2.

An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.

Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D.

J Bone Oncol. 2019 Sep 18;19:100261. doi: 10.1016/j.jbo.2019.100261. eCollection 2019 Dec.

3.

A di-iron protein recruited as an Fe[II] and oxygen sensor for bacterial chemotaxis functions by stabilizing an iron-peroxy species.

Muok AR, Deng Y, Gumerov VM, Chong JE, DeRosa JR, Kurniyati K, Coleman RE, Lancaster KM, Li C, Zhulin IB, Crane BR.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):14955-14960. doi: 10.1073/pnas.1904234116. Epub 2019 Jul 3.

PMID:
31270241
4.

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R.

Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016. Epub 2019 Apr 24.

5.

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.

Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD.

Clin Cancer Res. 2019 May 1;25(9):2769-2782. doi: 10.1158/1078-0432.CCR-18-2202. Epub 2019 Jan 22.

PMID:
30670488
6.

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R, Cameron D.

J Bone Oncol. 2018 Sep 27;13:123-135. doi: 10.1016/j.jbo.2018.09.008. eCollection 2018 Nov.

7.

Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.

Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE.

J Pathol. 2019 Mar;247(3):381-391. doi: 10.1002/path.5197. Epub 2019 Jan 25.

8.

Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer.

Handforth C, Burkinshaw R, Freeman J, Brown JE, Snowden JA, Coleman RE, Greenfield DM.

Support Care Cancer. 2019 May;27(5):1755-1763. doi: 10.1007/s00520-018-4410-z. Epub 2018 Aug 25.

PMID:
30143894
9.

Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.

Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS.

Cancer Res. 2018 Sep 15;78(18):5300-5314. doi: 10.1158/0008-5472.CAN-18-0548. Epub 2018 Jul 31.

10.

Current perspectives on bone metastases in castrate-resistant prostate cancer.

Logothetis C, Morris MJ, Den R, Coleman RE.

Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4. Review.

11.

The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.

Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF.

Eur J Cancer. 2017 Dec;87:58-64. doi: 10.1016/j.ejca.2017.10.001. Epub 2017 Nov 5.

12.

Advances in the management of HER2-positive early breast cancer.

Baselga J, Coleman RE, Cortés J, Janni W.

Crit Rev Oncol Hematol. 2017 Nov;119:113-122. doi: 10.1016/j.critrevonc.2017.10.001. Epub 2017 Oct 4. Review.

13.

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S.

Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30516-X. doi: 10.1016/j.eururo.2017.06.021. [Epub ahead of print]

14.

Direct detection of Leishmania from clinical samples.

Waitumbi JN, Bast J, Nyakoe N, Magiri C, Quintana M, Takhampunya R, Schuster AL, Van de Wyngaerde MT, McAvin JC, Coleman RE.

US Army Med Dep J. 2017 Jan-Jun;(1-17):60-64.

PMID:
28511275
15.

GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.

Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists.

Ann Oncol. 2017 Aug 1;28(8):1811-1816. doi: 10.1093/annonc/mdx184.

16.

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.

Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C.

Ann Oncol. 2017 May 1;28(5):1090-1097. doi: 10.1093/annonc/mdx044.

17.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. Review.

18.

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.

Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE.

Eur J Cancer. 2017 Jan;71:1-6. doi: 10.1016/j.ejca.2016.10.020. Epub 2016 Dec 6.

19.

Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study.

Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D, Coleman RE.

J Bone Oncol. 2016 Oct 24;9:48-54. doi: 10.1016/j.jbo.2016.10.005. eCollection 2017 Nov.

20.

IL-1 drives breast cancer growth and bone metastasis in vivo.

Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P.

Oncotarget. 2016 Nov 15;7(46):75571-75584. doi: 10.18632/oncotarget.12289.

21.

Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

Winter MC, Tidy JA, Hills A, Ireson J, Gillett S, Singh K, Hancock BW, Coleman RE.

Gynecol Oncol. 2016 Dec;143(3):565-570. doi: 10.1016/j.ygyno.2016.10.001. Epub 2016 Oct 15.

PMID:
27756557
22.

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.

Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, Widmark A, Thuresson M, Xu L, Germino J, Sartor O.

Clin Genitourin Cancer. 2017 Feb;15(1):42-52.e8. doi: 10.1016/j.clgc.2016.07.027. Epub 2016 Aug 8.

23.

Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer.

Coleman RE.

Oncology (Williston Park). 2016 Aug;30(8):695-702. Review.

24.

Management and Outcomes of Patients with Stage I and IlIl Low-Risk Gestational Trophoblastic Neoplasia Treated in Sheffield, UK, from 1997-2006.

Macdonald MC, Hancock BW, Winter MC, Coleman RE, Tidy JA.

J Reprod Med. 2016 Aug;61(7-8):341-346.

PMID:
30408379
25.

LONGITUDINAL EVALUATION OF MALARIA EPIDEMIOLOGY IN AN ISOLATED VILLAGE IN WESTERN THAILAND: I. STUDY SITE AND ADULT ANOPHELINE BIONOMICS.

Zollner G, Sattabongkot J, Vaughan JA, Kankaew P, Robert LL, Thimasarn K, Sithiprasasna R, Coleman RE.

Southeast Asian J Trop Med Public Health. 2016 May;47(3):341-65.

PMID:
27405117
26.

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D.

Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002. Epub 2016 Jun 22.

27.

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, Staudacher K, Thuresson M, Parker C.

Prostate. 2016 Jul;76(10):905-16. doi: 10.1002/pros.23180. Epub 2016 Mar 23.

28.

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.

Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJ, Thomas G, Coleman RE.

J Bone Oncol. 2016 Feb 11;5(1):43-9. doi: 10.1016/j.jbo.2016.02.003. eCollection 2016 Mar.

29.

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.

Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C.

Ann Oncol. 2016 May;27(5):868-74. doi: 10.1093/annonc/mdw065. Epub 2016 Feb 23.

30.

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N.

Trials. 2016 Feb 3;17:63. doi: 10.1186/s13063-016-1195-6. No abstract available.

31.

Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.

Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA.

Breast Cancer Res Treat. 2016 Jan;155(2):303-11. doi: 10.1007/s10549-016-3684-4. Epub 2016 Jan 19.

32.

Late spontaneous resolution of persistent molar pregnancy.

Taylor F, Short D, Harvey R, Winter MC, Tidy J, Hancock BW, Savage PM, Sarwar N, Seckl MJ, Coleman RE.

BJOG. 2016 Jun;123(7):1175-81. doi: 10.1111/1471-0528.13867. Epub 2016 Jan 15.

33.

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE.

J Natl Cancer Inst. 2016 Jan 12;108(4). doi: 10.1093/jnci/djv360. Print 2016 Apr. Erratum in: J Natl Cancer Inst. 2016 Mar;108(3). pii: djw017. doi: 10.1093/jnci/djw017.

34.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.

Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JWR, Kohno N.

Eur J Cancer. 2016 Feb;54:57-63. doi: 10.1016/j.ejca.2015.10.011. Epub 2015 Dec 23.

35.

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.

Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.

36.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I.

Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review.

PMID:
26681681
37.

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N.

Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7. Erratum in: Trials. 2016;17:63.

38.

Detection of Dengue Virus in Mosquito Extracts and Human Clinical Samples Using a Field Expedient Molecular Platform.

Pal S, Richardson JH, Murphy JR, Krairojananan P, Kongtak P, Jaichapor B, Kankaew P, Ekanayake S, Davis TJ, Maserang DL, Teng DH, Crisp RJ, Wu SJ, Coleman RE, McAvin JC, Swaby JA.

Mil Med. 2015 Sep;180(9):937-42. doi: 10.7205/MILMED-D-14-00428.

PMID:
26327544
39.

The Role of Computed Tomography Scanning of the Thorax in the Initial Assessment of Gestational Trophoblastic Neoplasia.

Price JM, Lo C, Abdi S, Winter MC, Coleman RE, Tidy J, Hancock BW.

Int J Gynecol Cancer. 2015 Nov;25(9):1731-6. doi: 10.1097/IGC.0000000000000534.

PMID:
26270122
40.

Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study.

Greenfield DM, Blewitt A, Coleman RE, Walsh JS, Snowden JA, Ross RJM, Han TS.

Clin Endocrinol (Oxf). 2016 Feb;84(2):296-304. doi: 10.1111/cen.12869. Epub 2015 Sep 1.

PMID:
26248973
41.

The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.

Wilson C, Ottewell P, Coleman RE, Holen I.

BMC Cancer. 2015 Feb 14;15:55. doi: 10.1186/s12885-015-1066-7.

42.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Gelmon KA, Boyle FM, Kaufman B, Huntsman DG, Manikhas A, Di Leo A, Martin M, Schwartzberg LS, Lemieux J, Aparicio S, Shepherd LE, Dent S, Ellard SL, Tonkin K, Pritchard KI, Whelan TJ, Nomikos D, Nusch A, Coleman RE, Mukai H, Tjulandin S, Khasanov R, Rizel S, Connor AP, Santillana SL, Chapman JA, Parulekar WR.

J Clin Oncol. 2015 May 10;33(14):1574-83. doi: 10.1200/JCO.2014.56.9590. Epub 2015 Mar 16.

PMID:
25779558
43.

A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.

Taylor F, Short D, Winter MC, Tidy J, Savage PM, Sarwar N, Hancock BW, Seckl MJ, Coleman RE.

Gynecol Oncol. 2015 Feb;136(2):258-63. doi: 10.1016/j.ygyno.2014.12.024. Epub 2014 Dec 24.

PMID:
25542400
44.

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.

Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K.

Ann Oncol. 2015 Feb;26(2):368-74. doi: 10.1093/annonc/mdu519. Epub 2014 Nov 25. Erratum in: Ann Oncol. 2015 Jun;26(6):1274.

45.

Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.

Pepek JM, Marks LB, Berry MF, Ready NE, Gee NG, Coleman RE, D'Amico TA, Crawford J, Kelsey CR.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):79-84. doi: 10.1016/j.prro.2014.05.002. Epub 2014 Jun 14.

PMID:
25413417
46.

Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice.

Goyal A, Dodwell D, Reed MW, Coleman RE.

J Clin Oncol. 2014 Dec 1;32(34):3902. doi: 10.1200/JCO.2014.57.3717. Epub 2014 Sep 22. No abstract available.

PMID:
25245444
47.

Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experience.

Ireson J, Singh K, Gillett S, Hills A, Everard J, Winter M, Coleman RE, Tidy J, Hancock BW.

J Reprod Med. 2014 May-Jun;59(5-6):195-8.

PMID:
24937956
48.

Endocrine aspects of bone metastases.

Hofbauer LC, Rachner TD, Coleman RE, Jakob F.

Lancet Diabetes Endocrinol. 2014 Jun;2(6):500-12. doi: 10.1016/S2213-8587(13)70203-1. Epub 2014 Jan 24. Review.

PMID:
24880565
49.

Impact of (18)F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry.

Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Quinn B, Coleman RE.

J Nucl Med. 2014 Jul;55(7):1054-61. doi: 10.2967/jnumed.113.135475. Epub 2014 May 12.

50.

Supplemental Content

Loading ...
Support Center